Clarient
Date | Investors | Amount | Round |
---|---|---|---|
$40.0m | Early VC | ||
N/A | $10.9m | Early VC | |
$587m Valuation: $587m | Acquisition | ||
Total Funding | $50.9m |
Related Content
Recent News about Clarient
EditClarient Inc. is a leading provider of cancer genetic testing and information services, specializing in offering one of the most comprehensive oncology-focused testing menus globally. The company serves physicians by providing advanced diagnostic tools to help in the diagnosis and treatment of cancer. Additionally, Clarient Inc. operates a Pharma Services division that caters to pharmaceutical clients involved in clinical trials and drug development. Headquartered in Fort Myers, Florida, the company is expanding its capabilities with a new state-of-the-art oncology laboratory and global headquarters. Clarient Inc. generates revenue through its Clinical Services and Pharma Services divisions, with the former seeing a 7.9% increase in revenue to $93.0 million in the second quarter of 2020. The company collaborates with other industry leaders, such as QIAGEN, to offer specialized diagnostic tests, including those for advanced breast cancer patients. Clarient Inc. operates in the healthcare and biotechnology markets, focusing on precision medicine and personalized cancer care.
Keywords: oncology, genetic testing, cancer diagnosis, clinical trials, drug development, precision medicine, personalized care, diagnostic tools, healthcare, biotechnology.